Mirae Asset has earned about $22 million in profit through the sale of BioNTech, a company spokesman said on April 16. In July last year, Mirae Asset invested $15 million in BioNTech, which holds candidate materials for the mRNA-based treatment.
BioNTech is a German-based biotech company that has and develops candidate materials for messenger RNA-based treatments.
BioNTech was listed on NASDAQ about three months after Mirae Asset's investment in the American depositary receipt (ADR) method, and Mirae Asset Group realized profits when the mandatory protection period expired this time.
The sale is the first investment withdrawal case of Mirae Asset-Naver Asia Growth Fund, which was formed in June 2018.
Mirae Asset Group added that assets it invested abroad are beginning to generate investment results, with profits realized by selling the Cologne City Hall in Germany and the TB Building in Frankfurt last year.
Founded in 2008 in Mainz, Germany, BioNTech is developing treatments for various disease groups, including cancer, infectious diseases and rare diseases, through technical partnerships with global companies.
